EVALUATING COSTS WITH UNMEASURED CONFOUNDING: A SENSITIVITY ANALYSIS FOR THE TREATMENT EFFECT
- PMID: 24587844
- PMCID: PMC3935434
- DOI: 10.1214/13-AOAS665
EVALUATING COSTS WITH UNMEASURED CONFOUNDING: A SENSITIVITY ANALYSIS FOR THE TREATMENT EFFECT
Abstract
Estimates of the effects of treatment on cost from observational studies are subject to bias if there are unmeasured confounders. It is therefore advisable in practice to assess the potential magnitude of such biases. We derive a general adjustment formula for loglinear models of mean cost and explore special cases under plausible assumptions about the distribution of the unmeasured confounder. We assess the performance of the adjustment by simulation, in particular, examining robustness to a key assumption of conditional independence between the unmeasured and measured covariates given the treatment indicator. We apply our method to SEER-Medicare cost data for a stage II/III muscle-invasive bladder cancer cohort. We evaluate the costs for radical cystectomy vs. combined radiation/chemotherapy, and find that the significance of the treatment effect is sensitive to plausible unmeasured Bernoulli, Poisson and Gamma confounders.
Keywords: SEER-Medicare; Sensitivity analysis; censored costs.
Figures
Similar articles
-
Estimating cost-effectiveness from claims and registry data with measured and unmeasured confounders.Stat Methods Med Res. 2019 Jul;28(7):2227-2242. doi: 10.1177/0962280218759137. Epub 2018 Feb 22. Stat Methods Med Res. 2019. PMID: 29468944 Free PMC article.
-
How unmeasured confounding in a competing risks setting can affect treatment effect estimates in observational studies.BMC Med Res Methodol. 2019 Jul 31;19(1):166. doi: 10.1186/s12874-019-0808-7. BMC Med Res Methodol. 2019. PMID: 31366331 Free PMC article.
-
Evaluating the impact of unmeasured confounding with internal validation data: an example cost evaluation in type 2 diabetes.Value Health. 2013 Mar-Apr;16(2):259-66. doi: 10.1016/j.jval.2012.10.012. Epub 2013 Jan 23. Value Health. 2013. PMID: 23538177
-
Assessing the impact of unmeasured confounders for credible and reliable real-world evidence.Pharmacoepidemiol Drug Saf. 2020 Oct;29(10):1219-1227. doi: 10.1002/pds.5117. Epub 2020 Sep 14. Pharmacoepidemiol Drug Saf. 2020. PMID: 32929830 Review.
-
A tutorial on the use of instrumental variables in pharmacoepidemiology.Pharmacoepidemiol Drug Saf. 2017 Apr;26(4):357-367. doi: 10.1002/pds.4158. Epub 2017 Feb 27. Pharmacoepidemiol Drug Saf. 2017. PMID: 28239929 Review.
Cited by
-
Estimating cost-effectiveness from claims and registry data with measured and unmeasured confounders.Stat Methods Med Res. 2019 Jul;28(7):2227-2242. doi: 10.1177/0962280218759137. Epub 2018 Feb 22. Stat Methods Med Res. 2019. PMID: 29468944 Free PMC article.
-
Illustration of the Impact of Unmeasured Confounding Within an Economic Evaluation Based on Nonrandomized Data.MDM Policy Pract. 2017 Mar 16;2(1):2381468317697711. doi: 10.1177/2381468317697711. eCollection 2017 Jan-Jun. MDM Policy Pract. 2017. PMID: 30288418 Free PMC article.
-
Cost-effectiveness of revascularization strategies: the ASCERT study.J Am Coll Cardiol. 2015 Jan 6;65(1):1-11. doi: 10.1016/j.jacc.2014.09.078. J Am Coll Cardiol. 2015. PMID: 25572503 Free PMC article.
-
Nested g-computation: A causal approach to analysis of censored medical costs in the presence of time-varying treatment.J R Stat Soc Ser C Appl Stat. 2020 Nov;69(5):1189-1208. doi: 10.1111/rssc.12441. Epub 2020 Aug 25. J R Stat Soc Ser C Appl Stat. 2020. PMID: 34108743 Free PMC article.
-
Propensity score and doubly robust methods for estimating the effect of treatment on censored cost.Stat Med. 2016 May 30;35(12):1985-99. doi: 10.1002/sim.6842. Epub 2015 Dec 17. Stat Med. 2016. PMID: 26678242 Free PMC article.
References
-
- Arah OA, Chiba Y, Greenland S. Bias formulas for external adjustment and sensitivity analysis of unmeasured confounders. Ann Epidemiol. 2008;18:637–646. - PubMed
-
- Axelson O, Steenland K. Indirect methods of assessing the effects of tobacco use in occupational studies. Am J Ind Med. 1988;13:105–118. - PubMed
-
- Bang H, Tsiatis AA. Estimating medical costs with censored data. Biometrika. 2000;87:329–343.
-
- Bang H, Tsiatis AA. Median regression with censored cost data. Biometrics. 2002;58:643–649. - PubMed
-
- Baris D, Karagas MR, Verrill C, Johnson A, Andrew AS, Marsit CJ, Schwenn M, Colt JS, Cherala S, Samanic C, Waddell R, Cantor KP, Schned A, Rothman N, Lubin J, Fraumeni JF, Hoover RN, Kelsey KT, Silverman DT. A case-control study of smoking and bladder cancer risk: Emergent patterns over time. J Natl Cancer Inst. 2009;101:1553–1561. - PMC - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources